Abstract
Primary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents.
| Original language | English |
|---|---|
| Pages (from-to) | 175-185 |
| Number of pages | 11 |
| Journal | Cancer Letters |
| Volume | 248 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 18 2007 |
Fingerprint
Keywords
- Breast cancer
- Primary chemotherapy
- Primary endocrine therapy
- Primary targeted therapy
ASJC Scopus subject areas
- Cancer Research
- Molecular Biology
- Oncology
Cite this
Primary systemic therapy for operable breast cancer : A review of clinical trials and perspectives. / Guarneri, Valentina; Frassoldati, Antonio; Giovannelli, Simona; Borghi, Francesca; Conte, PierFranco.
In: Cancer Letters, Vol. 248, No. 2, 18.04.2007, p. 175-185.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Primary systemic therapy for operable breast cancer
T2 - A review of clinical trials and perspectives
AU - Guarneri, Valentina
AU - Frassoldati, Antonio
AU - Giovannelli, Simona
AU - Borghi, Francesca
AU - Conte, PierFranco
PY - 2007/4/18
Y1 - 2007/4/18
N2 - Primary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents.
AB - Primary systemic therapy represents the standard of care for locally advanced breast cancer and has becoming an attractive alternative in earlier stages. A part from the proven advantage of increasing the rate of breast conservative surgery, the up front use of systemic therapy can allow for an in vivo test of treatment sensitivity, and response to primary treatment discriminates patients at different prognosis. This review will summarize the more relevant data on the preoperative treatment with chemotherapy, hormonal therapy and targeted agents.
KW - Breast cancer
KW - Primary chemotherapy
KW - Primary endocrine therapy
KW - Primary targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=33847255913&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847255913&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2006.07.001
DO - 10.1016/j.canlet.2006.07.001
M3 - Article
C2 - 16919869
AN - SCOPUS:33847255913
VL - 248
SP - 175
EP - 185
JO - Cancer Letters
JF - Cancer Letters
SN - 0304-3835
IS - 2
ER -